• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗中性粒细胞胞浆抗体(p-ANCA)阳性在特发性肺纤维化中的临床及预后意义:一项回顾性观察研究

Clinical and Prognostic Significance of p-ANCA Positivity in Idiopathic Pulmonary Fibrosis: A Retrospective Observational Study.

作者信息

Libra Alessandro, Muscato Giuseppe, Ielo Giuseppe, Spicuzza Lucia, Palmucci Stefano, Fagone Evelina, Fruciano Mary, Gili Elisa, Sambataro Gianluca, Vancheri Carlo

机构信息

Regional Referral Centre for Rare Lung Disease, Department of Clinical and Experimental Medicine, University Hospital "Policlinico-San Marco", University of Catania, 95123 Catania, Italy.

Radiology Unit I, Department of Medical Surgical Sciences and Advanced Technologies "GF Ingrassia", University Hospital "Policlinico-San Marco", University of Catania, 95123 Catania, Italy.

出版信息

Diagnostics (Basel). 2023 May 27;13(11):1882. doi: 10.3390/diagnostics13111882.

DOI:10.3390/diagnostics13111882
PMID:37296734
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10253038/
Abstract

Perinuclear Anti Neutrophil Cytoplasmic Antibody (p-ANCA) is a serological marker of Microscopic Polyangiitis (MPA), a vasculitis associated with lung involvement potentially mimicking Idiopathic Pulmonary Fibrosis (IPF). In this study, we evaluated the role of p-ANCA in predicting clinical evolution and prognosis in a cohort of IPF patients. In this observational, retrospective, case-control study, we compared 18 patients with an IPF diagnosis and p-ANCA positivity with 36 patients with seronegative IPF, matched for age and sex. IPF patients with and without p-ANCA showed similar lung function decline during the follow-up, but IPF p-ANCA+ showed better survival. Half of IPF p-ANCA+ patients were classified as MPA for the development of renal involvement (55%) or skin signs (45%). The progression towards MPA was associated with high levels of Rheumatoid Factor (RF) at baseline. In conclusion, p-ANCA, mainly when associated with RF, could predict the evolution of Usual Interstitial Pneumonia (UIP) towards a definite vasculitis in patients, with a better prognosis compared with IPF. In this view, ANCA testing should be included in the diagnostic workup of UIP patients.

摘要

核周型抗中性粒细胞胞浆抗体(p-ANCA)是显微镜下多血管炎(MPA)的血清学标志物,MPA是一种与肺部受累相关的血管炎,可能酷似特发性肺纤维化(IPF)。在本研究中,我们评估了p-ANCA在预测一组IPF患者临床进展和预后中的作用。在这项观察性、回顾性、病例对照研究中,我们将18例诊断为IPF且p-ANCA阳性的患者与36例年龄和性别相匹配的血清阴性IPF患者进行了比较。有和没有p-ANCA的IPF患者在随访期间肺功能下降相似,但IPF p-ANCA阳性患者的生存率更高。一半的IPF p-ANCA阳性患者因出现肾脏受累(55%)或皮肤体征(45%)而被归类为MPA。向MPA的进展与基线时高水平的类风湿因子(RF)相关。总之,p-ANCA,主要是与RF相关时,可预测普通型间质性肺炎(UIP)患者向明确血管炎的演变,与IPF相比预后更好。据此,ANCA检测应纳入UIP患者的诊断检查中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67b6/10253038/20f4cf9ec8cc/diagnostics-13-01882-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67b6/10253038/7df02cbab5fd/diagnostics-13-01882-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67b6/10253038/bb133e0dc7c2/diagnostics-13-01882-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67b6/10253038/98c4fbe5956e/diagnostics-13-01882-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67b6/10253038/86abd4292863/diagnostics-13-01882-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67b6/10253038/20f4cf9ec8cc/diagnostics-13-01882-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67b6/10253038/7df02cbab5fd/diagnostics-13-01882-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67b6/10253038/bb133e0dc7c2/diagnostics-13-01882-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67b6/10253038/98c4fbe5956e/diagnostics-13-01882-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67b6/10253038/86abd4292863/diagnostics-13-01882-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67b6/10253038/20f4cf9ec8cc/diagnostics-13-01882-g005.jpg

相似文献

1
Clinical and Prognostic Significance of p-ANCA Positivity in Idiopathic Pulmonary Fibrosis: A Retrospective Observational Study.抗中性粒细胞胞浆抗体(p-ANCA)阳性在特发性肺纤维化中的临床及预后意义:一项回顾性观察研究
Diagnostics (Basel). 2023 May 27;13(11):1882. doi: 10.3390/diagnostics13111882.
2
Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study.肺纤维化患者在骨髓过氧化物酶抗中性粒细胞胞质抗体相关性肾炎中的计算机断层扫描表现为普通间质性肺炎模式的预后:一项回顾性单中心研究。
BMC Pulm Med. 2019 Nov 1;19(1):194. doi: 10.1186/s12890-019-0969-5.
3
Clinical features and prognosis of microscopic polyangiitis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis.显微镜下多血管炎合并普通型间质性肺炎与特发性肺纤维化的临床特征及预后比较
Clin Respir J. 2019 Jul;13(7):460-466. doi: 10.1111/crj.13032. Epub 2019 May 16.
4
Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis.特发性间质性肺炎与抗中性粒细胞胞浆抗体相关性间质性肺炎的临床特征比较。
Respirology. 2016 Jul;21(5):920-6. doi: 10.1111/resp.12763. Epub 2016 Mar 19.
5
Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias.特发性间质性肺炎中髓过氧化物酶-抗中性粒细胞胞质抗体的临床意义。
PLoS One. 2018 Jun 21;13(6):e0199659. doi: 10.1371/journal.pone.0199659. eCollection 2018.
6
Risk of progression of idiopathic pulmonary fibrosis to connective tissue disease: a long-term observational study in 527 patients.特发性肺纤维化进展为结缔组织病的风险:527 例患者的长期观察性研究。
Clin Rheumatol. 2021 Jun;40(6):2447-2456. doi: 10.1007/s10067-021-05659-x. Epub 2021 Mar 22.
7
Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis.特发性肺纤维化病程中髓过氧化物酶抗中性粒细胞胞质抗体阳性和显微镜下多血管炎的发生率。
Respir Med. 2013 Apr;107(4):608-15. doi: 10.1016/j.rmed.2013.01.006. Epub 2013 Feb 19.
8
Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis.特发性肺纤维化患者抗中性粒细胞胞浆抗体阳性转化与显微镜下多血管炎的发生。
BMJ Open Respir Res. 2015 Jan 9;2(1):e000058. doi: 10.1136/bmjresp-2014-000058. eCollection 2015.
9
Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor.抗中性粒细胞胞质抗体相关性血管炎中的普通型间质性肺炎:一个不良预后因素。
J Autoimmun. 2020 Jan;106:102338. doi: 10.1016/j.jaut.2019.102338. Epub 2019 Sep 27.
10
Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist.从肺科医生的角度看抗中性粒细胞胞浆抗体相关性血管炎的肺部受累。
Clin Exp Nephrol. 2013 Oct;17(5):667-671. doi: 10.1007/s10157-012-0710-7. Epub 2012 Nov 28.

引用本文的文献

1
Clinical Insights and Therapeutic Strategies for the Treatment of Interstitial Lung Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Trends and Future Directions.抗中性粒细胞胞浆抗体相关血管炎患者间质性肺疾病治疗的临床见解与治疗策略:当前趋势与未来方向
J Clin Med. 2025 Jun 30;14(13):4631. doi: 10.3390/jcm14134631.
2
Clinical significance of anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonia: a retrospective observational study.抗中性粒细胞胞浆抗体在特发性间质性肺炎中的临床意义:一项回顾性观察研究。
BMC Pulm Med. 2025 May 29;25(1):271. doi: 10.1186/s12890-025-03736-4.
3

本文引用的文献

1
Interstitial pneumonia with autoimmune features and histologic usual interstitial pneumonia treated with anti-fibrotic versus immunosuppressive therapy.具有自身免疫特征的间质性肺炎和组织学上的普通间质性肺炎采用抗纤维化与免疫抑制治疗。
Respir Investig. 2023 May;61(3):297-305. doi: 10.1016/j.resinv.2023.01.007. Epub 2023 Feb 28.
2
Functional respiratory impairment and related factors in patients with interstitial pneumonia with autoimmune features (IPAF): Multicenter study from NEREA registry.具有自身免疫特征的间质性肺炎(IPAF)患者的功能性呼吸障碍及相关因素:NEREA 登记处的多中心研究。
Respir Res. 2023 Jan 18;24(1):19. doi: 10.1186/s12931-023-02317-5.
3
Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis and Goodpasture Syndrome.
抗中性粒细胞胞质抗体相关性血管炎和 Goodpasture 综合征肺部表现的发病机制。
Int J Mol Sci. 2024 May 12;25(10):5278. doi: 10.3390/ijms25105278.
4
Advances in Diagnostics and Management of Respiratory System Diseases.呼吸系统疾病诊断与管理的进展
Diagnostics (Basel). 2023 Dec 21;14(1):20. doi: 10.3390/diagnostics14010020.
5
Outcomes and prognosis of progressive pulmonary fibrosis in patients with antineutrophil cytoplasmic antibody-positive interstitial lung disease.抗中性粒细胞胞质抗体阳性的间质性肺疾病患者的进行性肺纤维化的结局和预后。
Sci Rep. 2023 Oct 17;13(1):17616. doi: 10.1038/s41598-023-45027-0.
Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.
类风湿关节炎相关间质性肺病的治疗结果:一项真实世界、多中心研究免疫抑制对肺功能轨迹的影响。
Chest. 2023 Apr;163(4):861-869. doi: 10.1016/j.chest.2022.11.035. Epub 2022 Dec 5.
4
Interstitial Pneumonia with Autoimmune Features (IPAF): time to redefine the classification criteria.具有自身免疫特征的间质性肺炎(IPAF):是时候重新定义分类标准了。
Expert Rev Clin Immunol. 2023 Feb;19(2):131-133. doi: 10.1080/1744666X.2023.2134119. Epub 2022 Oct 11.
5
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.特发性肺纤维化(更新版)和成人进展性肺纤维化:美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会临床实践指南。
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.
6
ANCA-associated vasculitis in idiopathic pulmonary fibrosis: A case report and brief review of the literature.特发性肺纤维化合并抗中性粒细胞胞浆抗体相关性血管炎:病例报告并文献复习。
Medicine (Baltimore). 2022 Mar 4;101(9):e29008. doi: 10.1097/MD.0000000000029008.
7
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis.2022 年美国风湿病学会/欧洲抗风湿病联盟显微镜下多血管炎分类标准。
Ann Rheum Dis. 2022 Mar;81(3):321-326. doi: 10.1136/annrheumdis-2021-221796. Epub 2022 Feb 2.
8
Variables Associated With Response to Therapy in Patients With Interstitial Pneumonia With Autoimmune Features.特发性间质性肺炎伴自身免疫特征患者对治疗反应的相关因素。
J Clin Rheumatol. 2022 Mar 1;28(2):84-88. doi: 10.1097/RHU.0000000000001808.
9
Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association.间质性肺疾病与抗髓过氧化物酶抗体:并非简单关联。
J Clin Med. 2021 Jun 9;10(12):2548. doi: 10.3390/jcm10122548.
10
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.吡非尼酮治疗非特发性肺纤维化的进展性肺纤维化间质性肺疾病患者(RELIEF):一项双盲、随机、安慰剂对照、2b 期试验。
Lancet Respir Med. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30.